Cosentyx (Secukinumab) for the Treatment of Adult Onset Pityriasis Rubra Pilaris

Part of paid clinical trials in Scottsdale, Arizona.

Sponsor
Mayo Clinic
Study ID
NCT03342573
Phase
PHASE1
Status
Completed

Conditions

  • PITYRIASIS RUBRA PILARIS

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Cosentyx — DRUG
    Cosentyx 300 mg SQ week 0-4, then every q4 weeks for a total of 28 weeks.

Study Details

The primary objective of this study is to assess the potential effectiveness of Cosentyx in the treatment of adult-onset Pityriasis Rubra Pilaris or PRP.

Key Dates

Start date
Apr 1, 2018
Status verified
Feb 2022
Primary completion
Jan 1, 2022
Completion
Feb 1, 2022

Study Design

Enrollment
12 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Single Arm
    Patients with a biopsy proven diagnosis of PRP

Primary Outcome Measure

PASI-75 [ Time Frame: 28 weeks ]

Locations (2)

FacilityCityStateZIPSite coordinators
Mayo Clinic in ArizonaScottsdaleArizona85259-
Mayo Clinic in FloridaJacksonvilleFlorida32224-

Find similar trials in Scottsdale, AZ

By research site
Mayo Clinic in Arizona· Scottsdale, AZMayo Clinic in Florida· Jacksonville, FL

Related Studies